India, Aug. 12 -- RTW Biotech Opportunities Ltd. (RTW.L) on Wednesday announced that its private portfolio company Avere Therapeutics agreed to merge with NextCure Inc. (NXTC) in an all-stock transaction.
The transaction is expected to close by year-end.
The combined company will operate as Avere Therapeutics and trade on Nasdaq under the ticker AVRX.
Avere is also raising a total of $820 million through two private placements, including a previously announced $320 million placement and a new $500 million placement.
The company will participate in both offerings, with its total investment expected to be $5.9 million.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The proceeds from the placements a...